Stan Wang, Thymmune CEO

Re­gen­er­a­tive cell biotech Thym­mune launch­es with back­ing from George Church, John Maraganore

Thym­mune Ther­a­peu­tics is go­ing af­ter “the most im­por­tant or­gan you’ve nev­er heard of,” ac­cord­ing to Pil­lar VC’s Thomas de Vlaam.

The Cam­bridge, MA-based biotech has raised $7 mil­lion in seed fund­ing to push its thymic cell ther­a­py through pre­clin­i­cal stud­ies, it an­nounced Wednes­day. Thym­mune was found­ed in 2019 by famed Har­vard ge­neti­cist George Church’s lab alum­ni Stan Wang, who is al­so the biotech’s CEO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.